Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04484857 · ClinicalTrials.gov registry record · Phase 3
Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants
A Phase 3 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 283
- Enrollment target
NCT04484857 is a Phase 3 study that has completed, run by Kyntra Bio. The registered enrollment target is 283 participants.
The verdict
NCT04484857, a Phase 3 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 283 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of roxadustat dosing regimens among hemodialysis participants converted from erythropoiesis stimulating agent (ESA) therapy or who are ESA-naïve.
Interventions
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2021-09-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04484857
The ClinicalTrials.gov registry entry for NCT04484857 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Roxadustat is the first listed.
NCT04484857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04484857 about?
NCT04484857 is a clinical study titled "Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants". The purpose of this study is to assess the safety and effectiveness of roxadustat dosing regimens among hemodialysis participants converted from erythropoiesis stimulating agent (ESA) therapy or who are ESA-naïve.
What is the current status of trial NCT04484857?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 283 participants. The study started on 2020-07-22. Estimated completion is 2021-09-17.
What interventions are being tested in trial NCT04484857?
The interventions under investigation include: Roxadustat (DRUG).
Who is sponsoring clinical trial NCT04484857?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.